Audrey Sternberg

Using regorafenib after hepatocellular carcinoma progression on sorafenib in the post–liver transplantation setting produced overall survival effects similar to those of patients without liver transplant, according to results presented at the American Association for the Study of Liver Diseases’ 2018 Liver Meeting.

Results of a multi-institutional, retrospective analysis showed that radiotherapy in localized follicular lymphoma resulted in 68.9% of patients having no disease progression at 5 years with fewer than 2% of patients experiencing an in-field relapse, according to a study published in <em>Blood</em>.

A retrospective analysis of survival data from patients with metastatic non&ndash;small cell lung cancer showed that patients who received treatment at academic centers had better survival rates than those treated at community-based centers, and this disparity was more pronounced when patients were stratified by histology.

The dose-adjusted EPOCH-R chemotherapy regimen induced either a complete or partial response in 87% of patients with aggressive B-cell lymphomas with an <em>MYC</em> rearrangement, a population that has had historically poor prognoses with rituximab plus R-CHOP.

Genetic aberrations across cancer types were the driving force behind drug approvals in 2018.

Nonadherence to endocrine therapy may explain why black women with hormone receptor&ndash;positive breast cancer have higher mortality rates than white women, despite historically lower incidence rates.

Neoadjuvant chemotherapy with a dose-dense, or accelerated, course of methotrexate, vinblastine, doxorubicin, and cisplatin was more likely to produce a complete pathologic response and extend overall survival than any other chemotherapy regimen in patients with bladder cancer treated with cystectomy, according to a study published in <em>JAMA Oncology</em>.

Patients with hydroxyurea resistant/intolerant polycythemia vera without palpable splenomegaly who were treated with ruxolitinib experienced a 3-fold increase in the likelihood of achieving hematocrit control over patients treated with physician&rsquo;s-choice therapy, with a majority of those patients maintaining their response at 80 weeks, according to findings of a phase III prospective trial.

Failed clinical trials in glioblastoma are hampering the path toward novel treatment regimens in this difficult-to-treat malignancy and old approaches to clinical trial design are reducing the appetite for involvement, according to Erik P. Sulman, MD, PhD.

Based on data from the phase III TAM-01 trial presented at the 41st Annual San Antonio Breast Cancer Symposium, investigators concluded that giving women&nbsp;diagnosed with breast intraepithelial neoplasia a lower dose of&nbsp;tamoxifen following surgery could be as effective and less toxic than the current standard dose.

The immunomodulating agent lenalidomide induced a complete response in 74% of patients with high tumor burden follicular lymphoma when used in combination with rituximab and a 4-drug chemotherapy regimen, according to a recent study.

Patients with metastatic renal and urothelial bladder cancer who receive antibiotics concomitantly with immune checkpoint inhibitors have shorter progression-free survival and&nbsp;overall survival rates than patients who do not, according to a poster presented at the European Congress on Immunotherapies in Cancer&trade; conference, hosted by Physicians&rsquo; Education Resource&reg;, LLC, September 21 and 22, 2018, in Barcelona, Spain.

Leading lung cancer researcher and clinician, Vassiliki A. Papadimitrakopoulou, MD, is the recipient of the 2018 Addario Lectureship Award presented by The Bonnie J. Addario Lung Cancer Foundation for her groundbreaking clinical research in immunotherapy.

An expert in hematologic malignancies, Harry Erba, MD, PhD, has been appointed director of both the Leukemia Program and Phase I Development in Hematologic Malignancies in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine at the Duke Cancer Institute in Durham, North Carolina.